Integrated serum pharmacochemistry, pharmacokinetics, and network analysis to explore active components of BuShao Tiaozhi Capsule on hyperlipidemia
Open Access
- 3 January 2025
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1444967
Abstract
BuShao Tiaozhi Capsule (BSTZC), a novel drug in China, has been used to treat hyperlipidemia (HLP) in clinical practice for many years. Despite our previous studies suggesting that BSTZC can treat HLP, there is a lack of a rapid and systematic method to explore its active components. Therefore, in this study, we aimed to investigate the active components and mechanisms of BSTZC in treating HLP by integrating serum pharmacology, pharmacokinetics, network analysis, and experimental validation. We first established UPLC fingerprints, calibrated 23 common peaks, and identified 13 common peaks, and the similarity was greater than 0.99 for 10 batches. A total of nine metabolites from BSTZC were identified in serum and considered as PK markers. The pharmacokinetic parameters of the PK markers were compared between the control group and the model group through the pharmacokinetics study to determine the dynamic changes of representative components in rats. Compared with the control group, the Cmax and AUC0→t of OXY, IVT, IVL, and KPF-3-G were significantly higher (P< 0.05); the AUC0→∞ of OXY, PN, and IVT was significantly higher (P< 0.05); and the t1/2 of IVT, SA, and KPF-3-G was significantly different (P< 0.05). In vivo experiments showed that BSTZC and its active components could effectively alleviate lipid metabolism disorders and liver injury, with obvious lipid-lowering effects. Further studies showed that BSTZC alleviated HLP by inhibiting the PI3K/Akt signaling pathway, which was consistent with the results of the network analysis study. Our results revealed the active components and mechanisms of BSTZC in the treatment of HLP, which could provide useful information to guide the clinical application of BSTZC.Keywords
This publication has 40 references indexed in Scilit:
- Estrogen Deficiency Aggravates Fluoride-Induced Liver Damage and Lipid Metabolism Disorder in RatsBiological Trace Element Research, 2021
- Mechanisms and Treatment of Dyslipidemia in DiabetesCurrent Cardiology Reports, 2021
- Pharmacokinetic-Pharmacodynamic Modeling of the Antioxidant Activity of Quzhou Fructus Aurantii Decoction in a Rat Model of HyperlipidemiaBiomedicine & Pharmacotherapy, 2020
- Antioxidant and pancreatic lipase inhibitory effects of flavonoids from different citrus peel extracts: An in vitro studyFood Chemistry, 2020
- Apigenin and naringenin regulate glucose and lipid metabolism, and ameliorate vascular dysfunction in type 2 diabetic ratsEuropean Journal of Pharmacology, 2016
- Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemiaHepatology, 2014
- Simultaneous determination of five free and total flavonoids in rat plasma by ultra HPLC–MS/MS and its application to a comparative pharmacokinetic study in normal and hyperlipidemic ratsJournal of Chromatography B, 2014
- Determination of free and glucuronidated kaempferol in rat plasma by LC–MS/MS: Application to pharmacokinetic studyJournal of Chromatography B, 2010
- Glucuronidation of flavonoids by recombinant UGT1A3 and UGT1A9Biochemical Pharmacology, 2008
- Obesity: Genetic, molecular, and environmental aspectsAmerican Journal of Medical Genetics Part A, 2007